JI-101

Description: JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor beta (PDGFR-beta), and ephrin type-B receptor 4 (EphB4). Target: VEGFR, PDGFR, Ephrin Receptor. Smiles: COc1ccc(Br)cc1NC(=O)Nc1cccc2n(Cc3ccnc(N)c3)ccc12. References: Mark L. Wade, Neeraj Agarwal et al. A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-beta, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort. Investigational New Drugs, December 2015, Volume 33, Issue 6, pp 1217-1224